New drugs get together to list AIDS or become chronic diseases

Since 2018, GSK, Johnson & Johnson, cutting-edge biology and other anti-AIDS drugs have piled on the market. Recently, Geely Dejie Fukang is officially on the market in China. It is the first approved single tablet based on TAF / FTC for the treatment of AIDS in China.
For many new anti-AIDS drugs on the market in China, Geely Global Vice President, China General Manager Luo Yongqing believes that this can benefit more infected people. "We will be guided by the needs that are not met, so that more patients can use the product."
On October 20, Wang Fusheng, academician of the Chinese Academy of Sciences and a reporter from the Third and Second Hospital of the Chinese People's Liberation Army, pointed out to the 21st century economic report that effective drug innovation has transformed AIDS from a fatal disease into a chronic disease that can be managed for a long massage
However, despite the increasing number of new drugs on the market, many pharmaceutical companies and experts said that the current situation of China's anti-AIDS drug market restrictions have not been fundamentally resolved. In China, the current AIDS drugs are mainly free drugs. In 2004, China promulgated the "four exemptions and one care" policy for AIDS patients, and formulated the "National Free AIDS Antiviral Drug Treatment Manual", but it covers less than 1/3 of the drug varieties listed.
Anti AIDS new drugs get together and go club
In 2017, the General Office of the State Council issued the "Thirteenth Five-Year Plan of Action" for the Control and Prevention of AIDS in China. One of the goals mentioned in the plan is that "more than 90% of the infected persons and patients are diagnosed and aware of their infection status. The proportion of infected persons and patients who meet the treatment conditions receiving antiviral treatment is more than 90%, and the successful rate of treatment of infected persons and patients receiving antiviral treatment is more than 90%.
Over the past decade, China has invested a lot of resources in AIDS prevention and control. With the increasing coverage of antiviral treatment, the mortality rate of AIDS has decreased from 18.4% in 2005 to 4.6% in 2015. As of 2017, there were about 758 thousand cases of HIV/AIDS surviving in China.
However, Wang Fusheng believes that AIDS patients in addition to surviving, but also need to have a better quality of life, more dignified to live. Effective drug innovation has transformed AIDS from a lethal disease into a long-term manageable chronic disease.
With the accelerated pace of Drug Reviews in China, new AIDS drugs have been "listed" from the beginning of the year. Five months after the official approval of the State Food and Drug Administration, on January 22, GSK announced that its holding joint venture company, ViiV Health Care, a new anti-AIDS drug, Suimekai, was officially listed in the mainland of China. This is a monolithic compound preparation for the first complete treatment in the field of HIV treatment in the mainland of China.
On July 13, the frontier biopharmaceutical industry independently developed China's first new anti-AIDS drug Aiconin, the world's first anti-AIDS long-term integration inhibitor approved for sale. In September 2nd, the global conference of the leading biopharmaceuticals Ike Ning was held in sauna
On July 23, Johnson & Johnson Pharmaceutical Co., Ltd. announced that Puzeli was approved to be used in combination with other antiretroviral drugs to treat adult patients infected with human immunodeficiency virus (HIV).
On August 6, Gillide announced that the State Drug Administration (SDA) approved the use of Jiefukang in the treatment of HIV-1-infected adults and adolescents (over 12 years old, weighing more than 35 kilograms), which is also the first single-dose regimen approved for the treatment of HIV based on TAF/FTC in China. In October 20th, Czechoslovakia officially launched.
The reason why Czechoslovakia can be approved is based on the 144 week data of the two 3 phase double-blind studies. "Clinical trials have shown that in 144 weeks of treatment, Geofukang showed a sustained and long-term viral inhibition, and its safety is expected to be widely applicable to HIV-infected people." Peking Union Medical College Hospital professor Li Taisheng said.
It is expected to turn into chronic bar
With the discovery of treatments and medicines, AIDS is becoming a chronic disease and may even be cured. But AIDS patients need to continue medication after their illness.
China's current AIDS drugs are mainly free drugs. In 2004, China launched a policy of "four exemption and one concern" for AIDS patients. Among them, "four exemptions" refers to: to meet the anti-viral treatment of AIDS patients with free antiviral drugs; voluntary AIDS counseling and testing personnel for free testing and counseling; HIV-infected pregnant women with free maternal and child blocking drugs; AIDS orphans exempted from school spa
"One care" refers to the state to provide treatment and care for people infected with HIV and patients, economic difficulties of AIDS patients and their families in accordance with the policy of subsistence allowance; support productive capacity of HIV-infected people and patients to engage in productive activities within their means to increase their income.
The state has also formulated the "National Free AIDS Antiviral Drug Treatment Manual" (hereinafter referred to as the "Free Manual"), to provide free drug treatment for AIDS patients. However, it is understood that more than 20 anti-AIDS drugs have been listed in China, but only 8 are included in the "free manual".
Director Jiang Tianjun of the Center for Diagnosis, Treatment and Research of Infectious Diseases in the Third and Second Hospital of the People's Liberation Army told 21st Century Economic Reporter that the current cost of medication for an AIDS patient is about 2,000 yuan a month. In fact, many AIDS patients are also accompanied by other complications, and the cost will be higher.
The cost of treatment is also a huge problem that plagued some AIDS patients.neil massage
Addressú║ 181 Lane 1 Building,Changshou Road,near Shaanxi Northshanghai,china
Copyright Gay Asia and Asian Gay resources by Neil massage